Aside from its enzymatic function in the glycolytic pathway, -enolase (ENO1) has been implicated in numerous diseases, including metastatic cancer, autoimmune disorders, ischaemia and bacterial infection. The disease-related roles of ENO1 are mostly attributed to its immunogenic capacity, DNA-binding ability and plasmin(ogen) receptor function, which are significantly affected by its three-dimensional structure and surface properties, rather than its enzymatic activity. Here, the crystal structure of human ENO1 (hENO1) is presented at 2.2 Å resolution. Despite its high sequence similarity to other enolases, the hENO1 structure exhibits distinct surface properties, explaining its various activities, including plasmin-(ogen) and DNA binding.
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Introduction
Enolase, a key enzyme in the glycolytic pathway, is ubiquitously present in a wide range of organisms from bacteria to mammals. Mammals contain three enolase isotypes, denoted , and . -Enolase (ENO1) is found in a variety of tissues, while -enolase (ENO3) is exclusively expressed in muscle tissues and -enolase (ENO2) is present in neurons and neuroendocrine tissues (Pancholi, 2001) . ENO1 (EC 4.2.1.11) has been the focus of recent research owing to its multifunctional roles in diseases (Gerlt et al., 2005; Kim & Dang, 2005; Glasner et al., 2006; Liu & Shih, 2007) such as cancers (Katayama et al., 2006; Kanemoto et al., 2006; Gruber-Olipitz et al., 2004) , autoimmune disorders (Mosca et al., 2006; Weleber et al., 2005; Kinloch et al., 2005; Gitlits et al., 2001) , infections (Bergmann et al., 2005; Ehinger et al., 2004) and ischaemia (Anand & Stead, 2005) . The disease-related roles of ENO1 mostly rely on its immunogenic properties (Fujii et al., 2005; Yoneda et al., 2007) , DNA-binding ability (Al-Giery & Brewer, 1992; Subramanian & Miller, 2000; Wang et al., 2005) and plasmin(ogen) receptor function (Miles et al., 1991; Ehinger et al., 2004; Bergmann et al., 2005) .
ENO1 has been identified on the cell surface as well as within the nucleus and cytosol. However, the signal peptides responsible for its localization remain to be identified. ENO1 is highly expressed in tumour cells (Altenberg & Greulich, 2004; Altenberg et al., 2006) and may recruit plasminogen in the tumour environment. Plasminogen bound to the cell surface is converted to plasmin by plasminogen activators and subsequently activates procollagenase to collagenase. This enzyme system is involved in wound healing, tissue remodelling, embryogenesis and cell spreading in the body by degrading fibrin and extracellular matrix (Plow et al., 1995) .
The role of ENO1 in tumour-cell invasion and metastasis may be explained by a similar process (Reuning et al., 1998) . Enolases on bacterial surfaces participate in the invasion of pathogenic bacteria into tissues, resulting in systemic infection (Bergmann et al., 2005; Plow et al., 1995) . These enzymes additionally act as autoantigens to cause encephalopathy (Fujii et al., 2005; Yoneda et al., 2007) , retinopathy (Weleber et al., 2005) and rheumatoid arthritis (Kinloch et al., 2005) . The DNA-binding ability of ENO1 mainly depends on its myc promoter-binding protein-1 (MBP-1) domain (Aoki et al., 2006; Subramanian & Miller, 2000; Feo et al., 2000; Sedoris et al., 2007) . MBP-1, an alternative translation product of ENO1 mRNA, binds to the c-myc P2 promoter to downregulate cmyc expression (Subramanian & Miller, 2000; Feo et al., 2000) .
While the crystal structures of bacterial enolases (Ehinger et al., 2004; Hosaka et al., 2003; Giotto et al., 2003) , yeast ENO1 (Zhang et al., 1997; Lebioda et al., 1989; Lebioda & Stec, 1988) and human ENO2 (-enolase; Chai et al., 2004) have been determined, those of human ENO1 (hENO1) and ENO3 (hENO3) have yet to be solved. To date, most structural analyses have focused on the active sites of the enolases, rather than the features related to DNA binding, plasmin-(ogen) receptor and immunogenic functions, with a few exceptions (Ehinger et al., 2004) . Recent reports have described noncatalytic multifunctionality of ENO1 in cancer metastasis, infection and autoimmune diseases (Liu & Shih, 2007; Kim & Dang, 2005; Pancholi, 2001) . Here, we resolve the crystal structure of hENO1, which displays surface properties that are distinct from those of other enolases despite high sequence similarity.
Materials and methods

Expression and purification
Human ENO1 cDNA encoding full-length protein (434 amino acids) was a gift from the 21C Human Gene Bank, Genome Research Center, KRIBB, Korea. The forward primer (5 0 -GGGAATTCCATATGTCTATTCTCAAGATC-CATGCC-3 0 ) and reverse primer (5 0 -CCGCTCGAGTTA-CTTGGCCAAGGGGTTTG-3 0 ) were designed based on the hENO1 DNA sequence, with NdeI and XhoI restriction sites, respectively, shown in bold. Human ENO1 was amplified by PCR using the primers described above and its cDNA as template. The PCR product was digested with NdeI and XhoI and subcloned into NdeI-XhoI-digested pET28a(+) vector (Novagen). The resulting N-terminally His-tagged full-length human ENO1 (hENO1) was expressed in Escherichia coli Rosetta (DE3) (Novagen). Expression of the His-tagged protein was induced by adding 1 mM IPTG at 291 K for 16 h. Cells were harvested by centrifugation at 3570g and sonicated in lysis buffer [50 mM Tris-HCl pH 7.5, 500 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 0.05%(v/v) -mercaptoethanol and 5% glycerol]. His-tagged hENO1 was purified by cobaltaffinity chromatography (Clontech). After removal of the His tag by thrombin digestion at 277 K for 20 h, crude hENO1 was purified using Mono Q ion-exchange column chromatography.
The hENO1 protein was further purified on a Sephacryl S-100 size-exclusion column (Amersham Pharmacia) by eluting in buffer containing 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 20 mM MgCl 2 , 1 mM PMSF and 0.05%(v/v) -mercaptoethanol. Pure hENO1 fractions were combined, concentrated to 20 mg ml À1 and used directly for crystallization.
Crystallization and data collection
Crystallization was performed at room temperature (291 K) using the hanging-drop vapour-diffusion method. Crystals were grown by mixing 1 ml hENO1 solution (20 mg ml À1 ) and an equal volume of reservoir solution [100 mM Tris-HCl pH 7.5 containing 20-24%(w/v) PEG 3350, 200 mM ammonium sulfate and 1 mM DTT]. Full-size hENO1 crystals were obtained after 3 d. X-ray diffraction data were collected on beamline 4A at Pohang Accelerator Laboratory (Pohang, Korea) using an ADSC Quantum 4 detector. The crystal diffracted to 2.2 Å resolution and belonged to space group P4 2 , with unit-cell parameters a = b = 192.8, c = 65.2 Å , = = = 90 . The diffraction data collected were processed and scaled with DENZO and SCALEPACK (Otwinowski & Minor, 1997) . Statistics of data collection and refinement are shown in Table 1 .
Structure solution and refinement
The hENO1 structure was determined by the molecularreplacement method using a dimeric human -enolase structure ( ( McCoy et al., 2005) . The best solution for the first dimer had a log-likelihood gain (LLG) of 1460 and a Z score for the translation function (TFZ) of 7275, whereas the best solution for the second dimer reached an LLG of 2062 with a TFZ Z score of 10171.
To avoid coupling between the working and test data sets, the test set (5%) for R free calculation was selected from 20 thin shells. The structure was refined using CNS (Brü nger et al., 1998) with the MLF target, while iterative manual building was performed using O (Jones et al., 1991) . As the four protomers in the asymmetric unit essentially adopt the same conformation, noncrystallographic symmetry restraints were applied during refinement and were released at the final stage. Water molecules were gradually added during refinement using the water-pick protocol implemented in CNS (Brü nger et al., 1998) . Strong electron densities that were not part of the protein were observed near the active sites of the four protomers. These were modelled as sulfate ions considering the crystallization conditions (Fig. 1b) . Statistics of data collection and structure refinement are summarized in Table 1 . The final R cryst and R free values are 19.2% and 21.4%, respectively. A Ramachandran plot drawn using PROCHECK (Laskowski et al., 1993) showed that 87.5% and 12.2% of all residues fell within the most favoured and additionally allowed regions, respectively. There were no residues in the disallowed region. The final model includes residues 1-432 of protomers A and B, residues 1-433 of protomer C, residues 1-431 of protomer D, 617 water molecules, eight magnesium ions and four sulfate ions. Fig. 1 was generated using PyMOL (http://www.pymol.org), BOB-SCRIPT (Esnouf, 1997) and MOLSCRIPT (Kraulis, 1991) .
Electrostatic potential surface
The surface potentials were calculated and visualized using the program GRASP, which contains rapid algorithms for the construction of rendered molecular surfaces and for solution of the Poisson-Boltzmann equation (Nicholls et al., 1991) . The electrostatic surface potentials were calculated with contours from À10kT e À1 (red) to +10kT e À1 (blue) (where k is Boltzmann's constant and T is temperature). Default Structure of hENO1. (a) Ribbon diagram of hENO1. Secondary-structural elements (helices, cyan; strands, magenta; loops, pink) assigned using PROCHECK are labelled. Bound magnesium and sulfate ions are depicted as ball-and-stick models. The boundaries of the secondary-structural elements are as follows: 1, 4-11; 2, 17-25; 3, 28-33; 4, 146-153; 5, 166-170; 6, 240-244; 7, 251-252; 8, 255-256; 9, 288-292; 10, 313-316; 11, 338-341; 12, 365-369; 13, 391-393; 1, 62-78; 2, 86-97; 3, 107-124; 4, 129-137; 5, 177-199; 6, 219-232; 7, 272-285; 8, 300-310; 9, 324-333; 10, 343-346; 11, 349-361; 12, 379-386; 13, 400-416. (b) Active site. A difference electron-density map (F o À F c ) around the active site omitted in map calculation was drawn using the refined model. The map was contoured at the 5.0 level. parameters in GRASP (exterior dielectric constant of 80, interior dielectric constant of 4, 0.0 M ionic concentration) were applied to this calculation. Charges were assigned to each ionisable residue, i.e. aspartate, glutamate, lysine and arginine, using the full.crg option as implemented in GRASP.
Results and discussion
Overall structure
The structure of hENO1 (Fig. 1a ) is essentially divided into N-terminal (residues 1-138) and C-terminal (residues 139-432) domains. The N-terminal domain comprises a three-stranded -sheet with three flanking -helices, while the C-terminal domain consists of an eightfoldbarrel. The global structure of hENO1 is markedly similar to that of the prototypical yeast enolase (Zhang et al., 1997; 63 .1% sequence identity and 78.8% sequence homology), which has been extensively characterized using biochemical and structural methods. Two types of yeast ENO1 structures have been reported, with 'open' and 'closed' conformations. Accordingly, the refined structure of hENO1 was superimposed on those of the two conformers. Superpositions were performed with the O program using a distance criterion of less than 3.8 Å for more than three consecutive C atoms. When the hENO1 structure was aligned with that of yeast ENO1 with the open confor-mation (PDB code 1ebh; Wedekind et al., 1995) , 410 of 432 C atoms were superimposed with a root-mean-square deviation of 1.2 Å , whereas alignment with the closed (or complexed) conformation structure (PDB code 1one; Larson et al., 1996) yielded a superposition of 432 C atoms with a root-meansquare deviation of 0.7 Å . These results imply that hENO1 adopts the closed conformation.
Some enolases show dimeric asymmetry, possibly representing negative cooperativity within the dimer (Chai et al., 2004) . However, all the C atoms of the four protomers in the asymmetric unit were superposed on each other with a rootmean-square deviation of less than 0.5 Å , discounting the possibility of negative cooperativity in hENO1. The potential plasmin(ogen)-binding surfaces of hENO1 (a) and spENO1 (b). The electrostatic potential surfaces of hENO1 and spENO1 are presented using the program GRASP. The spENO1 electrostatic surface was derived from the crystallographic coordinates of the S. pneumoniae enzyme (PDB code 1w6t). The electrostatic potentials were calculated with contours from À10kT e À1 (red) to +10kT e À1 (blue) and with an exterior dielectric constant of 80. Two binding sites with surrounding regions are bordered by yellow lines and several representative residues are labelled. Table 2 Comparison of putative plasmin(ogen)-binding sites between bacterial and mammalian enolases and fractional solvent accessibility (FSA).
Amino-acid residue number in plasmin(ogen)-binding motif † Enolase  250  251  252  253  254 255 256
.00 † The numbering was based on the amino-acid sequence of hENO1. ‡ Eno int/del is a mutated spENO1 which does not bind to plasminogen. This enzyme was prepared by replacing the two lysine residues in the internal plasminogen-binding motif with leucine as well as replacing Glu with Gly and by truncation of the C-terminal plasminogen-binding domain (Bergmann et al., 2003) . § The FSA of each amino acid in the hENO1 structure was calculated using the program QUANTA as the ratio of the side-chain fractional solvent accessibility for residue X to the fractional solvent accessibility obtained after reducing the structure to a Gly-X-Gly tripeptide.
Active-site structure
The active site of hENO1 consists of the L1 (residues 36-43), L2 (residues 156-162) and L3 (residues 262-270) loops, two magnesium ions bound to Glu292, Asp317, Asp244 and Ser39, and water molecules (Fig. 1b) . The common active (or closed) conformation of all enolases can be defined by the surrounding three loops (L1-L3) that encompass the active site, which would be occupied by potential substrates. Upon crystallization of hENO1 without the substrate, hENO1 adopted the closed conformation, which was possibly induced by the sulfate ion bound to the active site. Two magnesium ions and a sulfate ion in the active site were also located at similar positions to the corresponding atoms in the closed structure of yeast enolase (Larson et al., 1996) .
Comparison of the surface of hENO1 with those of other enolases
Both eukaryotic and bacterial -enolases have the ability to bind plasmin(ogen). To establish the mechanisms of plasmin-(ogen) binding, we generated a surface representation of hENO1 for comparison with that of Streptocoocus pneumoniae enolase 1 (spENO1; Fig. 2; Ehinger et al., 2004) .
The general features of the surface potentials were very different in hENO1 and spENO1. The surface of spENO1 showed a higher degree of negative potential compared with that of hENO1 (Fig. 2) . To date, two distinct binding sites have been identified and some similarities exist between the primary sequences of eukaryotic and bacterial -enolases. One binding site consists of 6-8 residues, including two anti- Comparison of electrostatic potentials for hENO1 (a) and hENO2 (b). Two points of view for each protein are presented, which are rotated by 180 along the y axis to each other. The different charged patches are labelled and bordered by solid yellow lines. The same calculation protocols as used in Fig. 2 were applied to this figure. parallel -strands (7 and 8), and the other is located at the C-terminus. The putative plasmin(ogen)-binding motif of hENO1 ( 250 FFRSGKY 256 ) includes three hydrophobic and two hydrophilic residues. We additionally calculated the sidechain fractional solvent accessibility (FSA) of each residue in the plasminogen-binding motif in order to gain an insight into the residues participating in interactions with other proteins ( Table 2) .
The side chains of the three hydrophobic residues (Phe250, Phe251 and Tyr256 of hENO1) are completely buried or have only a small fraction exposed (FSA < 0.3; Table 2 ), whereas the FSA values for the hydrophilic residues range from 0.34 to 0.97. These results imply that the mode of plasmin(ogen) binding is dominated by the polar interactions arising from a possible complementary fit of plasmin(ogen) to the enolase surface as previously reported for spENO1 (Bergmann et al., 2003) . Sequence alignment with available enolases shows that the residues within the two antiparallel -strands (7 and 8) are variable compared with other regions. Nevertheless, they also show the common features of containing two or three hydrophilic residues as described in a previous review (Pancholi, 2001) . At this stage, however, it cannot be excluded that the exact features of the plasminogenbinding site are influenced by conformational changes upon substrate binding. While precise comparisons are hampered by possible weak or disordered electron densities for the putative binding sites in spENO1, the binding site at the C-terminus is apparently blocked by tight octameric association within spENO1 (Ehinger et al., 2004) . As hENO1 forms a dimer, however, its C-terminus is exposed to solvent, explaining the distinct binding specificities for plasmin-(ogen). Chai et al. (2004) reported that human neuronal-specific enolase (hENO2) has a higher degree of negatively charged surface structure than hENO1 in order to maintain the resting potential of neurons, similar to other neuron-specific proteins. In this investigation, the authors had to rely on a structure of hENO1 generated by molecular modelling to explain the differences in the surface-charge distribution of hENO2 and hENO1. Determination of the crystal structure of hENO1 will facilitate a more reliable comparison. Interestingly, despite high sequence identity ($84%) between the two proteins, the charge distribution on the hENO1 surface is distinct from that of hENO2 (Fig. 3) . 11 positively charged residues of hENO1 on the surface are altered to either negatively charged (three) or neutral (eight) residues in hENO2. In addition, ten neutral residues of hENO1 are negatively charged in the neuronal enolase, explaining the higher pI value (7.38) of hENO1 compared with that of hENO2 (4.75). The positively charged surface of hENO1 is possibly related to its noncatalytic function. In particular, in view of its positively charged surface, hENO1 should display a stronger DNA-binding ability than hENO2. Additionally, the distinct surface properties of hENO1 may be responsible for other noncatalytic functions, such as plasmin(ogen) binding and autoantigen activity. Further biological experiments are required to confirm the validity of the above suggestions.
In summary, we have reported the hENO1 structure for the first time. Structural analyses revealed that hENO1 has surface properties that are distinct from those of other enolases despite high sequence identity. The results will afford a structural basis for understanding the multifunctional properties of ENO1. In addition, these results provide a good example of slight sequence diversities in proteins that manifest themselves as distinguishable surface properties which can cause the proteins to display totally different biological functions.
